Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.64 |
| ▸ | PPARG | P37231 | 9/20 | 0.64 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31407637 | 1.00 | PPARA (0.64) | PPARAPPARGCTSKCTSSPPARD | |
| SCHEMBL12475131 | 1.00 | PPARA (0.64) | PPARAPPARGCTSKCTSSPPARD | |
| Valine SCHEMBL2747379 | 0.91 | PPARA (0.56) | PPARAPPARGCTSKCTSSPPARD | |
| SCHEMBL23176836 | 0.91 | PPARA (0.60) | PPARAPPARGCTSKCTSSPPARD | |
| SCHEMBL12305805 | 0.90 | CTSK (0.57) | PPARAPPARGCTSKCTSSPPARD | |
| SCHEMBL8239148 | 0.90 | CTSK (0.57) | PPARAPPARGCTSKCTSSPPARD | |
| SCHEMBL16384170 | 0.89 | PPARA (0.54) | PPARAPPARGCTSKCTSSPPARD | |
| SCHEMBL28578196 | 0.89 | PPARA (0.55) | PPARAPPARGCTSKCTSSPPARD | |
| SCHEMBL25054091 | 0.89 | PPARA (0.55) | PPARAPPARGCTSKCTSSPPARD | |
| SCHEMBL441305 | 0.87 | PPARA (0.67) | PPARAPPARGCTSKCTSSPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-2673281-B1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-8933018-B2 | Boron containing polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2673281-A1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20130316943-A1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2012109164-A1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130316943-A1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | PPARA 2661/4885PPARG 3081/4885CTSK 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.